Ernesto Fedele

List of Publications by Year
in descending order

96 papers	3,550 citations	109137 35 h-index	149479 56 g-index
96 all docs	96 docs citations	96 times ranked	4077 citing authors

#	Article	IF	Citations
1	The Amyloid Cascade Hypothesis in Alzheimerâ€™s Disease: Itâ€™s Time to Change Our Mind. Current Neuropharmacology, 2017, 15, 926-935.	1.4	253
2	Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology, 2006, 66, 1824-1829.	1.5	173
3	In vivo studies of the cerebral glutamate receptor/NO/cGMP pathway. Progress in Neurobiology, 1999, 58, 89-120.	2.8	155
4	GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses. British Journal of Pharmacology, 2011, 164, 2054-2063.	2.7	128
5	Subthalamic stimulation activates internal pallidus: Evidence from cGMP microdialysis in PD patients. Annals of Neurology, 2005, 57, 448-452.	2.8	122
6	Evidence of a role for cyclic ADP-ribose in calcium signalling and neurotransmitter release in cultured astrocytes. Journal of Neurochemistry, 2001, 78, 646-657.	2.1	117
7	Cyclo-oxygenase-1 and -2 differently contribute to prostaglandinâ€ƒE2 synthesis and lipid peroxidation after in vivo activation of N-methyl-d-aspartate receptors in rat hippocampus. Journal of Neurochemistry, 2005, 93, 1561-1567.	2.1	114
8	Biochemical and electrophysiological changes of substantia nigra pars reticulata driven by subthalamic stimulation in patients with Parkinson's disease. European Journal of Neuroscience, 2006, 23, 2923-2928.	1.2	114
9	Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D. Neuropharmacology, 2014, 77, 120-130.	2.0	102
10	LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex. Frontiers in Molecular Neuroscience, 2014, 7, 49.	1.4	82
11	Acetylcholine release from rat hippocampal slices is modulated by 5-hydroxytryptamine. European Journal of Pharmacology, 1989, 165, 173-179.	1.7	73
12	Reduced L -dopa absorption and increased clinical fluctuations in Helicobacter pylori -infected Parkinson's disease patients. Neurological Sciences, 2001, 22, 89-91.	0.9	73
13	Nicotine administration stimulates the in vivo N-methyl-D -aspartate receptor/nitric oxide/cyclic GMP pathway in rat hippocampus through glutamate release. British Journal of Pharmacology, 1998, 125, 1042-1048.	2.7	72
14	In vivo activation of N-methyl-d-aspartate receptors in the rat hippocampus increases prostaglandin E2 extracellular levels and triggers lipid peroxidation through cyclooxygenase-mediated mechanisms. Journal of Neurochemistry, 2002, 81, 1028-1034.	2.1	70
15	In vivo microdialysis study of a specific inhibitor of soluble guanylyl cyclase on the glutamate receptor/nitric oxide/cyclic GMP pathway. British Journal of Pharmacology, 1996, 119, 590-594.	2.7	67
16	Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 46320.	1.6	63
17	Age-related decrease of the NMDA receptor-mediated noradrenaline release in rat hippocampus and partial restoration by D-cycloserine. European Journal of Pharmacology, 1993, 231, 129-134.	1.7	62
18	Amyloid-Î² Peptide Is Needed for cGMP-Induced Long-Term Potentiation and Memory. Journal of Neuroscience, 2017, 37, 6926-6937.	1.7	59

#	Article	IF	Citations
19	Electrophysiology and Pharmacology of Striatal Neuronal Dysfunction Induced by Mitochondrial Complex I Inhibition. Journal of Neuroscience, 2008, 28, 8040-8052.	1.7	54
20	Ectocellular in vitro and in vivo metabolism of cADP-ribose in cerebellum. Biochemical Journal, 1996, 320, 665-671.	1.7	53
21	Glutamate-mediated overexpression of CD38 in astrocytes cultured with neurones. Journal of Neurochemistry, 2004, 89, 264-272.	2.1	52
22	Mechanisms of glutamate release elicited in rat cerebrocortical nerve endings by â€˜pathologicallyâ€™ elevated extraterminal K+concentrations. Journal of Neurochemistry, 2007, 103, 952-961.	2.1	51
23	<scp>l</scp>â€Aspartate as an amino acid neurotransmitter: mechanisms of the depolarizationâ€induced release from cerebrocortical synaptosomes. Journal of Neurochemistry, 2009, 110, 924-934.	2.1	48
24	Helicobacter pylori-induced reduction of acute levodopa absorption in parkinson's disease patients. Annals of Neurology, 2001, 50, 686-687.	2.8	47
25	Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, 383-389.	1.1	46
26	The pharmacological blockade of medial forebrain bundle induces an acute pathological synchronization of the corticoâ€“subthalamic nucleusâ€“globus pallidus pathway. Journal of Physiology, 2009, 587, 4405-4423.	1.3	43
27	Microdialysis in Parkinsonian Patient Basal Ganglia: Acute Apomorphine-Induced Clinical and Electrophysiological Effects Not Paralleled by Changes in the Release of Neuroactive Amino Acids. Experimental Neurology, 2001, 167, 356-365.	2.0	42
28	Glutamic Acid and ?-Aminobutyric Acid Modulate Each Other's Release Through Heterocarriers Sited on the Axon Terminals of Rat Brain. Journal of Neurochemistry, 1993, 61, 222-230.	2.1	41
29	Nearly 30 Years of Animal Models to Study Amyotrophic Lateral Sclerosis: A Historical Overview and Future Perspectives. International Journal of Molecular Sciences, 2021, 22, 12236.	1.8	40
30	The NOS/sGC pathway in the rat central nervous system: a microdialysis overview. Neurochemistry International, 2004, 45, 787-797.	1.9	38
31	Preâ€synaptic nicotinic receptors evoke endogenous glutamate and aspartate release from hippocampal synaptosomes by way of distinct coupling mechanisms. British Journal of Pharmacology, 2010, 161, 1161-1171.	2.7	38
32	Transmitter Release Associated with Long-term Synaptic Depression in Rat Corticostriatal Slices. European Journal of Neuroscience, 1995, 7, 1889-1894.	1.2	37
33	cAMP, cGMP and Amyloid Î²: Three Ideal Partners for Memory Formation. Trends in Neurosciences, 2018, 41, 255-266.	4.2	36
34	Glycine stimulates [3H]noradrenaline release by activating a strychnine-sensitive receptor present in rat hippocampus. European Journal of Pharmacology, 1990, 184, 239-250.	1.7	35
35	An evaluation of the role of extracellular amino acids in the delayed neurodegeneration induced by quinolinic acid in the rat striatum. Neuroscience, 1993, 52, 911-917.	1.1	35
36	In vivo microdialysis study of GABAA and GABaB receptors modulating the glutamate receptor/NO/cyclic GMP pathway in the rat hippocampus. Neuropharmacology, 1997, 36, 1405-1415.	2.0	35

#	Article	IF	Citations
37	Benzodiazepine-Sensitive GABAA Receptors Limit the Activity of the NMDA/NO/Cyclic GMP Pathway. Journal of Neurochemistry, 2002, 75, 782-787.	2.1	35
38	[3H]Glycine uptake in rat hippocampus: kinetic analysis and autoradiographic localization. Brain Research, 1992, 572, 154-163.	1.1	34
39	Desensitization of AMPA receptors and AMPAâ€NMDA receptor interaction: an in vivo cyclic GMP microdialysis study in rat cerebellum. British Journal of Pharmacology, 1996, 117, 1133-1138.	2.7	34
40	Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment. Neurochemistry International, 2017, 105, 58-63.	1.9	33
41	A novel mechanism for cyclic adenosine monophosphateâ€“mediated memory formation: Role of amyloid beta. Annals of Neurology, 2014, 75, 602-607.	2.8	32
42	New insights into selective PDE4D inhibitors: 3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) oxime (GEBR-7b) structural development and promising activities to restore memory impairment. European Journal of Medicinal Chemistry, 2016, 124, 82-102.	2.6	31
43	Reduced GABA Content in the Motor Thalamus during Effective Deep Brain Stimulation of the Subthalamic Nucleus. Frontiers in Systems Neuroscience, 2011, 5, 17.	1.2	29
44	MicroRNA Alteration, Application as Biomarkers, and Therapeutic Approaches in Neurodegenerative Diseases. International Journal of Molecular Sciences, 2022, 23, 4718.	1.8	28
45	GABAA, but not NMDA, receptors modulate in vivo NO-mediated cGMP synthesis in the rat cerebral cortex. Neuropharmacology, 2004, 46, 480-489.	2.0	27
46	In vivo effects of phosphodiesterase inhibition on basal cyclic guanosine monophosphate levels in the prefrontal cortex, hippocampus and cerebellum of freely moving rats. Journal of Neuroscience Research, 2008, 86, 3338-3347.	1.3	25
47	Phosphodiesterase 4D: an enzyme to remember. British Journal of Pharmacology, 2015, 172, 4785-4789.	2.7	25
48	Leucineâ€rich repeat kinase 2 phosphorylation on synapsin I regulates glutamate release at preâ€synaptic sites. Journal of Neurochemistry, 2019, 150, 264-281.	2.1	25
49	Presynaptic Nicotinic Î±7 and Non-Î±7 Receptors Stimulate Endogenous GABA Release from Rat Hippocampal Synaptosomes through Two Mechanisms of Action. PLoS ONE, 2011, 6, e16911.	1.1	25
50	Presynaptic GLPâ€1 receptors enhance the depolarizationâ€evoked release of glutamate and GABA in the mouse cortex and hippocampus. BioFactors, 2018, 44, 148-157.	2.6	24
51	The clinical efficacy of L-DOPA and STN-DBS share a common marker: reduced GABA content in the motor thalamus. Cell Death and Disease, 2011, 2, e154-e154.	2.7	23
52	The glutamate receptor/no/cyclic gmp pathway in the hippocampus of freely moving rats: Modulation by cyclothiazide, interaction with gaba and the behavioural consequences. Neuropharmacology, 1997, 36, 1393-1403.	2.0	22
53	Exocytosis regulates trafficking of GABA and glycine heterotransporters in spinal cord glutamatergic synapses: a mechanism for the excessive heterotransporter-induced release of glutamate in experimental amyotrophic lateral sclerosis. Neurobiology of Disease, 2015, 74, 314-324.	2.1	22
54	Presynaptic Mechanisms Underlying the ?-Aminobutyric Acid-Evoked Receptor-Independent Release of [3H]Norepinephrine in Rat Hippocampus. Journal of Neurochemistry, 1989, 52, 1854-1858.	2.1	21

#	Article	IF	Citations
55	D-serine modulates the NMDA receptor/nitric oxide/cGMP pathway in the rat cerebellum during in vivo microdialysis. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 355, 43-47.	1.4	21
56	Cyclic adenosine monophosphate as an endogenous modulator of the amyloidâ€Î²2 precursor protein metabolism. IUBMB Life, 2013, 65, 127-133.	1.5	21
57	Antagonizing Î±7 nicotinic receptors with methyllycaconitine (MLA) potentiates receptor activity and memory acquisition. Cellular Signalling, 2019, 62, 109338.	1.7	21
58	Amyloid Î²: Walking on the dark side of the moon. Mechanisms of Ageing and Development, 2015, 152, 1-4.	2.2	20
59	The Novel Phosphodiesterase 9A Inhibitor BI 409306 Increases Cyclic Guanosine Monophosphate Levels in the Brain, Promotes Synaptic Plasticity, and Enhances Memory Function in Rodents. Journal of Pharmacology and Experimental Therapeutics, 2019, 371, 633-641.	1.3	19
60	Cholinergic modulation of [3H]dopamine release from dendrosomes of rat substantia nigra. Naunyn-Schmiedeberg's Archives of Pharmacology, 1991, 344, 275-80.	1.4	17
61	Synthesis, Biological Evaluation, and Molecular Modeling of New 3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-Dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) Related Phosphodiesterase 4D (PDE4D) Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 7061-7072.	2.9	17
62	Effects of phosphodiesterase inhibition on cortical spreading depression and associated changes in extracellular cyclic GMP. Biochemical Pharmacology, 2004, 67, 1619-1627.	2.0	16
63	In vivo NO/cGMP signalling in the hippocampus. Neurochemical Research, 2001, 26, 1069-1078.	1.6	15
64	Heterocarrier-mediated reciprocal modulation of glutamate and glycine release in rat cerebral cortex and spinal cord synaptosomes. European Journal of Pharmacology, 1994, 252, 61-67.	1.7	14
65	Synthesis, biological activities and pharmacokinetic properties of new fluorinated derivatives of selective PDE4D inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 3426-3435.	1.4	13
66	Enhanced Function and Overexpression of Metabotropic Glutamate Receptors 1 and 5 in the Spinal Cord of the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis during Disease Progression. International Journal of Molecular Sciences, 2019, 20, 4552.	1.8	13
67	Releaseâ€regulating dopamine autoreceptors in human cerebral cortex. British Journal of Pharmacology, 1993, 110, 20-22.	2.7	12
68	Alterations of glutamate release in the spinal cord of mice with experimental autoimmune encephalomyelitis. Journal of Neurochemistry, 2010, 115, 343-352.	2.1	12
69	Functional damage of dopamine nerve terminals following intrastriatal kainic acid injection. Brain Research, 1989, 480, 242-248.	1.1	11
70	Native human neocortex release-regulating dopamine D2 type autoreceptors are dopamine D2 subtype. European Journal of Neuroscience, 1999, 11, 2351-2358.	1.2	11
71	Memory Enhancers for Alzheimerâ€™s Dementia: Focus on cGMP. Pharmaceuticals, 2021, 14, 61.	1.7	11
72	Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug. European Journal of Neurology, 2004, 11, 593-606.	1.7	10

#	Article	IF	Citations
73	PDE4D inhibitors: A potential strategy for the treatment of memory impairment?. Neuropharmacology, 2014, 85, 290-292.	2.0	10
74	Altered fronto-striatal functions in the Gdi1-null mouse model of X-linked Intellectual Disability. Neuroscience, 2017, 344, 346-359.	1.1	10
75	Intracerebral administration of l-kynurenine decreases N-methyl-d-aspartate receptor-mediated production of cGMP in the cerebellum and hippocampus of unanaesthetized rats subjected to transcerebral microdialysis. Neuroscience Letters, 1999, 266, 81-84.	1.0	8
76	cGMP favors the interaction between APP and BACE1 by inhibiting Rab5 GTPase activity. Scientific Reports, 2020, 10, 1358.	1.6	8
77	Activation of brain nitric oxide synthase in depolarized human temporal cortex slices: differential role of voltage-sensitive calcium channels. British Journal of Pharmacology, 1997, 122, 930-934.	2.7	7
78	Acute and Chronic Dopaminergic Depletion Differently Affect Motor Thalamic Function. International Journal of Molecular Sciences, 2020, 21, 2734.	1.8	7
79	Autoradiographical evaluation of [3H]glycine uptake in rat forebrain: Cellular localization in the hippocampus. Neuroscience Letters, 1993, 161, 4-8.	1.0	6
80	Neuropeptide S inhibits release of 5-HT and glycine in mouse amygdala and frontal/prefrontal cortex through activation of the neuropeptide S receptor. Neurochemistry International, 2013, 62, 360-366.	1.9	6
81	Investigating the amyloid-beta enhancing effect of cGMP in neuro2a cells. Mechanisms of Ageing and Development, 2017, 166, 1-5.	2.2	6
82	Dopamine release and dopaminergic inhibition of acetylcholine release in rat striatal slices after nigro-striatal hemitransection and parenteral ganglioside administration. European Journal of Pharmacology, 1992, 213, 17-24.	1.7	5
83	Evaluating the role of hnRNPâ€C and FMRP in the cAMPâ€induced APP metabolism. BioFactors, 2015, 41, 121-126.	2.6	5
84	Protein kinase G phosphorylates the Alzheimer's diseaseâ€associated tau protein at distinct Ser/Thr sites. BioFactors, 2021, 47, 126-134.	2.6	5
85	Glycine enhances [3H]noradrenaline release from slices of rat hippocampus. Neuroscience Letters, 1990, 116, 352-356.	1.0	4
86	Evaluation of the mechanisms underlying the kainate-induced impairment of [3H]dopamine release in the rat striatum. European Journal of Pharmacology, 1993, 249, 71-77.	1.7	4
87	Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome. Neurological Sciences, 2004, 25, 53-6.	0.9	4
88	Isolation of Hydroxyoctaprenyl-1â€²,4â€²-hydroquinone, a new Octaprenylhydroquinone from the Marine Sponge Sarcotragus spinosulus and Evaluation of its Pharmacological Activity on Acetylcholine and Glutamate Release in the Rat Central Nervous System. Natural Product Communications, 2014, 9, 1934578X1400901.	0.2	4
89	Isolation of hydroxyoctaprenyl-1',4'-hydroquinone, a new octaprenylhydroquinone from the marine sponge Sarcotragus spinosulus and evaluation of its pharmacological activity on acetylcholine and glutamate release in the rat central nervous system. Natural Product Communications, 2014, 9, 1581-4.	0.2	4
90	Selective inhibition of phosphodiesterase <scp>4D</scp> increases tau phosphorylation at Ser214 residue. BioFactors, 2022, , .	2.6	3

#	Article	IF	Citations
91	Letter to the Editor. Journal of Neuroscience Methods, 2013, 212, 362.	1.3	2
92	A New Bistable Switch Model of Alzheimerâ€™s Disease Pathogenesis. International Journal of Molecular Sciences, 2022, 23, 7061.	1.8	2
93	Amyloid Beta and the Brain: Where Are We Now?. Journal of Biomolecular Research & Therapeutics, 2016, 5, .	0.2	1
94	Dbs in Parkinsonian Subthalamic Nucleus: Electrophysiological and Biochemical Changes. Advances in Behavioral Biology, 2002, , 3-12.	0.2	0
95	Stimulation of the amyloidâ€Î² precursor protein metabolism by cAMP. FASEB Journal, 2013, 27, 873.18.	0.2	0
96	Biochemical Markers of DBS-Induced Transition from â€œOffâ€•to â€œOnâ€•State in Parkinsonian Patients. , 2005, , 397-406.		0